Patent application number | Description | Published |
20160069457 | SLIDE RING SEAL - A slide ring seal has a slide ring, mounted in an axially movable manner, and a counterpart ring, wherein the slide ring and the counterpart ring each have sealing surfaces which bear against one another, wherein the sealing surface of the slide ring is situated opposite the sealing surface of the counterpart ring, and wherein the slide ring is pressed against the counterpart ring by a spring, wherein, with regard to refining and developing a slide ring seal of this type such that, while being inexpensive and easy to manufacture and having a construction involving a particularly small number of components, it seals off two chambers in a reliable and permanent manner, and the counterpart ring is formed in one piece with an axial projection which can be assigned to a shaft in order to fix the counterpart ring on the shaft. | 03-10-2016 |
20160084383 | SLIDE RING SEAL - A slide ring seal has a slide ring, supported such that the slide ring is axially movable, and a counter ring. The slide ring and the counter ring have respective sealing surfaces contacting one another. The slide ring sealing surface faces the counter ring sealing surface. The slide ring is pressed against the counter ring by a bellows-like spring element. The slide ring seal may be designed so the slide ring seal has an especially flexible slide ring and/or counter ring after economical and trouble-free production, the slide ring seal has at least one sealing surface with elevations or unevenness of a magnitude from 0.1 μm to W mm, W conforms to the formula W=0.03 Dm/s, wherein the average diameter Dm is the average of the circular-ring-shaped sealing surface's outside (Da) and inside (Di) diameter, and s is the slide ring or counter ring thickness. | 03-24-2016 |
Patent application number | Description | Published |
20110020376 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES - The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention. | 01-27-2011 |
20110020377 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES - The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention. | 01-27-2011 |
20110021559 | AMINOPYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES - The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention. | 01-27-2011 |
20110224197 | PYRIMIDINES AND PYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES - The present invention relates to compounds useful as inhibitors of protein kinases, such as inhibitors of GSK-3. The invention provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. The invention provides processes for preparing compounds of the invention. The invention provides methods of identifying compounds useful for treatment of diabetes, diabetic neuropathy, osteoporosis, Alzheimer's disease, Huntington's disease, Parkinson's disease, AIDS-associated dementia, bipolar disorder, amyotrophic lateral sclerosis, multiple sclerosis, schizophrenia, leukocytopenia, cardiomyocyte hypertrophy, stroke, post-stroke, spinal cord injury, traumatic brain injury, Charcot-Marie-Tooth, peripheral nerve regeneration, and rheumatoid arthritis. | 09-15-2011 |
20130245273 | AMINOPYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES - The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention. | 09-19-2013 |
20140194444 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES - The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention. | 07-10-2014 |
20140364450 | AMINOPYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES - The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention. | 12-11-2014 |
Patent application number | Description | Published |
20080281308 | Device and method for improved vascular laser treatment - An improved treatment set and an improved method for endovascular laser treatments are described. The treatment set comprises an introducer sheath or tip and an optical waveguide for allowing the treatment set to be guided within a blood vessel. The s introducer sheath itself acts as the guide wire in one embodiment of the procedure. The introducer includes a means for protecting the tip of the optical fiber while the set is being positioned within the vessel and protecting the introducer tip from damaging the vessel. The method includes the steps of inserting the introducer/optical waveguide combination into a blood vessel to be treated, positioning the distal end of the introducer at a proper position in the blood vessel; advancing the optical fiber through a protective cap and/or means, and irradiating the blood vessel, preferably while withdrawing the treatment set toward the point of insertion. In another embodiment, the introducer/optical fiber combination includes a monorail groove within which a guidewire resides, wherein the optical fiber resides within the introducer and is advanced along the guidewire prior to treatment. The invention is advantageous in that it is quicker, as it requires fewer parts and fewer steps for effective treatment than do prior art devices and methods. | 11-13-2008 |
20090028926 | Method and mixture for in vivo photochemical cross-linking of collagen - A method and a composition for photochemical cross linking of collagen by photoactive agent in-vivo are presented. The method includes a non-toxic photoactive formulation of the composition with collagen, which is administered to treatment area locally; followed by irradiation with suitable wavelength. In one of the embodiment liposomal formulated mTHPC is added to the collagen and is irradiated with a 652 nm laser, resulting in producing efficient collagen scaffolds with strengthen and stabilized microstructure, thus improving the physiochemical properties of the collagen scaffold. It improves the thermostability, mechanical property and swelling ratio of newly formed scaffold. Photochemical cross-linked collagens shows antimicrobial effect, when irradiated with suitable wavelength it disinfects the treatment site and curbs microbial growth. | 01-29-2009 |
20090131499 | PHOTODYNAMIC THERAPY FOR SKIN RELATED PROBLEMS - PhotoDynamic Therapy method is used to treat problems associated with pilosebaceous units including acne and other skin conditions. At least one liposomal-formulated, hydrophobic photosensitizer, such as a dihydro- or tetrahydro-porphyrin, is topically applied to acne affected regions, and is allowed to penetrate the hair follicle before being irradiated with a suitable wavelength of light energy overlapping the absorption spectrum of the selected photosensitizer. The photoactivated agent initiates a cytotoxic effect in the sebaceous gland, reducing excess oil production and destroying bacterial growth in the follicle thus subsiding inflammatory action. Scarring of the skin is minimized and the skin heals faster due to collagen cell stimulation. | 05-21-2009 |
20090171262 | Method and Mixture for In Vivo Photochemical Cross-Linking of Collagen - A method and a composition for photochemical cross linking of collagen by photoactive agent in-vivo are presented. The method includes a non-toxic photoactive formulation of the composition with collagen, which is administered to treatment area locally; followed by irradiation with suitable wavelength. In one of the embodiment liposomal formulated mTHPC is added to the collagen and is irradiated with a 652 nm laser, resulting in producing efficient collagen scaffolds with strengthen and stabilized microstructure, thus improving the physiochemical properties of the collagen scaffold. It improves the thermo stability, mechanical property and swelling ratio of newly formed scaffold. Photochemical cross-linked collagens shows antimicrobial effect, when irradiated with suitable wavelength it disinfects the treatment site and curbs microbial growth. | 07-02-2009 |
20110152745 | PDT TREATMENT METHOD FOR CELLULITES AND COSMETIC USE - Methods of treating cellulite by means of percutaneous application of a photosensitizer composition into the area of cellulite buildup followed by light illumination are presented. The photosensitizer can be combined with one or more cellular products including adipose cells and/or collagen that have been previously removed by liposuction. The cosmetic treatment method substantially reduces or removes localized lipodystrophies and/or flaccidity and/or cellulite by localized laser, LED, or other light irradiation of the area of treatment containing a photosensitizer, while minimizing trauma. | 06-23-2011 |
20110160642 | PEGYLATED LIPOSOMAL FORMULATIONS FOR PHOTODYNAMIC TREATMENT OF INFLAMMATORY DISEASES - A PDT treatment system designed to treat all types of human inflammatory disorders. A suitable drug delivery system is developed to target proliferating cells, at inflamed sites, populated with macrophages and other inflammatory mediators. The hydrophobic photosensitizer is loaded into the liposomal bilayer formed of synthetic phospholipids; at least one of the synthetic phospholipids is conjugated to polyethylene glycol (PEG) molecules, to prevent accumulation in the liver and spleen. Further, (PEG) formulated photosensitizer increases the circulatory half-life of the drug, enhances solubility, and modifies pharmacokinetic and pharmacodynamic properties. The formulation, thus, leads to a higher amount of delivered drug to the diseased target synovial tissue, increasing clinical effectiveness. In one embodiment, pegylated liposomes loaded with mTHPC are administered to diseased synovial joints, followed by light irradiation. Activated photosensitizer induces cytotoxic effect in the diseased synovial cells, thus preventing further inflammation and joint erosion and minimizing joint damage. | 06-30-2011 |
Patent application number | Description | Published |
20080214460 | Formulations for cosmetic and wound care treatments with photosensitizers as fluorescent markers - Photoactive materials, such as photosensitizers, are used as fluorescent markers for in vivo detection of the distribution of the injected filler material during cosmetic treatments. In one preferred embodiment, liposomal formulated temoporfin is used, as the photoactive component, in very small concentrations along with fillers for cosmetic and wound healing applications. Fillers, which can be used in the invention, include collagen, hyaluronic acids and other synthetic or natural products which are generally used in wound healing, scar reduction and other such medical applications. In a preferred embodiment, the formulated photosensitizer is coupled to the filler so that tracking is possible over longer periods of time A liposomal formulated photosensitizer is injected with the fillers into the treatment area, and is irradiated with laser light shortly after injection. The emitted fluorescence is measured by a special non-invasive device. Thereby it is possible to monitor the injection site and the distribution of the injected solution around the injection site. When irradiated with laser or other light source, the fluorescence of the photosensitizer is detected using a fluorescence detector, which permits tracking the filler at injection site and in the injection volume. | 09-04-2008 |
20090210038 | Medical Light Diffusers for High Power Applications and their Manufacture - A high power density light delivery device is presented that uses an optical fiber with a diffuser attached at a distal end for use in, for example, photodynamic therapy (PDT) and laser induced thermotherapy (LITT). Uniform scattering in the diffuser section is obtained by either inducing differences in refractive index profiles of the core or in the core-cladding interface with the use of scattering centers or nano-voids. Nano-voids are created in the core or core-cladding interface by focusing high power laser energy or picosecond/femtosecond laser pulses on the quartz fiber material to induce defects. A special method is used that writes defects into or near to the core/cladding boundary through the jacket, without the necessity to first remove the jacket and then recoat the fiber. The method uses a wavelength that is highly transmissive in the jacket and fiber but absorbed in the fiber at very short laser pulses with high peak power. These processes allow the use of high power laser energy and the emission of the resulting high power densities in quartz fibers. The disclosed optical fiber delivery system is suitable for high power applications that require optical fibers with high flexibility and strength and core diameters from about 50 to about 400 microns. | 08-20-2009 |
20110224660 | Diode Laser Induced Vapor/Plasma Mediated Medical Procedures and Device - An improved method and device for safe and efficient medical applications is provided. In a preferred embodiment, based on using the inherent benefits of laser diodes (such as efficient power generation from a reliable and compact solid state device), plasmas and high energy vapors are produced for medical applications with power levels and power densities sufficient to treat medical indications and avoid the creation of extensive damage zones. Transmissions means in different configurations are used to achieve a high power density, which is able to initiate plasma and high-energy vapor at the tip. Once a sparkless plasma and high energy vapor bubbles are formed, it is often found that it will also absorb other wavelengths in addition to the one that initiated it. As a consequence, other wavelengths more efficiently generated by diodes or diode pumped lasers may be added into the beam in order to improve treatment efficiency. For example, the 1470 nm wavelength can be used to produces sparkler-less plasma bubbles, together with the 980 nm wavelength to produce tissue vaporization and an excellent haemostasis effect. Once plasma and or high-energy vapors are in place, radiation from this zone determine tissue effects. In another embodiment, high peak power pulsed radiation is used. Wavelengths of 1470 nm, 1940 nm, or 1550 nm are preferred. Additionally it can be applied in combination with another wavelength with medium absorption in water such as 980 nm. In another embodiment a concentric double core fiber is used, in which the ignition radiation is guided in near single mode, inner core and the radiation used to maintain and enhance the pulse is guided into the surrounding second outer core. | 09-15-2011 |